CellGenTech Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $671K

  • Investors
  • 12

CellGenTech General Information

Description

Developer of a bio-venture company designed to provide therapeutic products. The company is developing processed cellular therapy outcomes using therapeutic genetically modified human adipocytes, whereby specific enzymes and functional proteins are replenished through the transplantation of human-derived cells, enabling patients to utilize their adipocytes to treat familial lecithin-cholesterol acyltransferase deficiency.

Contact Information

Website
www.cellgentech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 208 Chiba Oinaba Innovation Plaza
  • 1-8-15 Inohana, Chuo-ku
  • Chiba, 260-0856
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 208 Chiba Oinaba Innovation Plaza
  • 1-8-15 Inohana, Chuo-ku
  • Chiba, 260-0856
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CellGenTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 19-Oct-2023 $671K Completed Generating Revenue
9. Secondary Transaction - Private Completed Generating Revenue
8. Later Stage VC (Series F) 28-Oct-2021 Completed Generating Revenue
7. Accelerator/Incubator 01-Nov-2019 Completed Generating Revenue
6. Later Stage VC (Series E) 29-May-2019 Completed Generating Revenue
5. Later Stage VC (Series D) Completed Generating Revenue
4. Later Stage VC (Series C) Completed Generating Revenue
3. Early Stage VC (Series B) Completed Generating Revenue
2. Early Stage VC (Series A) $777K $777K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view CellGenTech’s complete valuation and funding history, request access »

CellGenTech Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
F Shares
E Shares
D Shares
C Shares
B Shares 4,280 $1062.93 $1062.93 1x $1062.93 16.46%
A Shares 1,250 $708.62 $708.62 1x $708.62 4.81%
To view CellGenTech’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

CellGenTech Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

CellGenTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025154708-A1 High concentration cell preservation liquid and high concentration cell preservation method Pending 15-Jan-2024
JP-7841789-B2 High-concentration cell preservation solution and high-concentration cell preservation method Active 15-Jan-2024
EP-4621056-A1 Cells for ex-vivo gene therapy that produce modified blood coagulation factor viii Pending 14-Nov-2022
US-20260191988-A1 Cells for ex-vivo gene therapy that produce modified blood coagulation factor viii Pending 14-Nov-2022
WO-2024106355-A1 Cells for ex-vivo gene therapy that produce modified blood coagulation factor viii Inactive 14-Nov-2022 A61P7/04
To view CellGenTech’s complete patent history, request access »

CellGenTech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CellGenTech Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
PF Capital Corporate Venture Capital Minority
STRIVE (VC Investor) Corporate Venture Capital Minority
Toho Holdings Holding Company Minority
ZACROS Corporation Minority
Healthcare Innovation Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

CellGenTech FAQs

  • When was CellGenTech founded?

    CellGenTech was founded in 2003.

  • Where is CellGenTech headquartered?

    CellGenTech is headquartered in Chiba, Japan.

  • What is the size of CellGenTech?

    CellGenTech has 12 total employees.

  • What industry is CellGenTech in?

    CellGenTech’s primary industry is Drug Discovery.

  • Is CellGenTech a private or public company?

    CellGenTech is a Private company.

  • What is CellGenTech’s current revenue?

    The current revenue for CellGenTech is .

  • How much funding has CellGenTech raised over time?

    CellGenTech has raised $23.8M.

  • Who are CellGenTech’s investors?

    PF Capital, STRIVE (VC Investor), Toho Holdings, ZACROS, and Healthcare Innovation are 5 of 12 investors who have invested in CellGenTech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process